• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Integrated understanding of molecular mechanisms of osteosarcoma development focusing on Myc super-enhancer

Research Project

Project/Area Number 21H03113
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section一般
Review Section Basic Section 57020:Oral pathobiological science-related
Research InstitutionNagasaki University

Principal Investigator

Ito Kosei  長崎大学, 医歯薬学総合研究科(歯学系), 教授 (00332726)

Co-Investigator(Kenkyū-buntansha) 神崎 秀嗣  秀明大学, 看護学部, 教授 (60807345)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2023: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2022: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2021: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
KeywordsTGFβ / Runx3 / Myc / スーパーエンハンサー / C/ebpα / 骨肉腫 / RUNX / p53 / TGF-β / Runx / c-Myc
Outline of Research at the Start

骨肉腫発症の分子メカニズムの根幹は、p53非存在下でのRunx3によるc-Mycの過剰発現であることが明らかになった。しかしその分子機構を司る微小環境要因はいまだ不明である。
我々はp53欠損骨肉腫細胞において、TGFβがRunx3依存的にMycの発現を強く誘導することを見出した。さらに、Myc遺伝子制御領域内に存在するTGFβ反応性のスーパーエンハンサー(TGFβ-MycSE)を同定した。そこで本研究は、TGFβシグナル伝達下におけるTGFβ-MycSEの意義、そしてTGFβ-MycSEにおけるRunx3の重要性を、遺伝子改変マウスを作出・解析することで検討する。

Outline of Final Research Achievements

Osx-Cre;p53f/f mice (herein; OS mice) have been widely utilized to study the mechanisms of osteosarcomagenesis. Using this line, we recently reported that Runx3 aberrantly upregulates c-Myc in the absence of p53, providing a molecular basis for osteosarcoma development. However, the environmental factors contributing to the Myc upregulation by Runx3 remain unknown. In this study, we found that TGFβ induces Myc upregulation in a Runx3-dependent manner through a Myc super-enhancer (MycSE) in p53-deficient cells. To further explore the significance of this finding in vivo, we generated the following genetically modified mouse lines; 1. a mouse line lacking MycSE (MycSEΔ), 2. a mouse line lacking the Runx binding sequence within MycSE (MycSERx m/m), and 3. a mouse line lacking the TGFβ type 2 receptor (Tgfbr2 flox). Each of these lines was crossed with OS mice. The crossed lines exhibited delayed osteosarcoma development and extended lifespan compared to OS mice.

Academic Significance and Societal Importance of the Research Achievements

本研究において、p53非存在下でRunx3によるc-Mycの発現誘導に必要なゲノム上のエレメントが明らかになり、TGFβ-Runx3-Mycの機軸が革新的な抗骨肉腫創薬ターゲットになりうることを、マウス生体レベルで確認できた。今後はこれらの成果をもとに、この機構のなかで中心的な役割をもつRunx3の特異的阻害剤、あるいは、Runx3と他の因子の相互作用を阻害する化合物を同定・開発することで、抗骨肉腫創薬につなげていきたい。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Annual Research Report
  • 2021 Annual Research Report
  • Research Products

    (9 results)

All 2023 2022 2021 Other

All Journal Article (5 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 5 results,  Open Access: 3 results) Presentation (2 results) Remarks (2 results)

  • [Journal Article] p53 Deficiency-Dependent Oncogenicity of Runx32023

    • Author(s)
      Ito Kosei、Otani Shohei、Date Yuki
    • Journal Title

      Cells

      Volume: 12 Issue: 8 Pages: 1122-1122

    • DOI

      10.3390/cells12081122

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Cellular dynamics of distinct skeletal cells and the development of osteosarcoma2023

    • Author(s)
      Otani Shohei、Ohnuma Mizuho、Ito Kosei、Matsushita Yuki
    • Journal Title

      Frontiers in Endocrinology

      Volume: 14 Pages: 1181204-1181204

    • DOI

      10.3389/fendo.2023.1181204

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] C/ebpα represses the oncogenic Runx3?Myc axis in p53-deficient osteosarcoma development2023

    • Author(s)
      Omori Keisuke、Otani Shohei、Date Yuki、Ueno Tomoya、Ito Tomoko、Umeda Masahiro、Ito Kosei
    • Journal Title

      Oncogene

      Volume: 42 Issue: 33 Pages: 2485-2494

    • DOI

      10.1038/s41388-023-02761-z

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Oncogenic Runx1ーMyc axis in p53-deficient thymic lymphoma.2022

    • Author(s)
      Date Y, Taniuchi I, Ito K
    • Journal Title

      Gene

      Volume: -

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma2021

    • Author(s)
      Otani Shohei, Date Yuki, Ueno Tomoya, Ito Tomoko, Kajikawa Shuhei, Omori Keisuke, Taniuchi Ichiro, Umeda Masahiro, Komori Toshihisa, Toguchida Junya, Ito Kosei
    • Journal Title

      Oncogene

      Volume: 41 Issue: 5 Pages: 683-691

    • DOI

      10.1038/s41388-021-02120-w

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] TGFβ signaling facilitates Myc upregulation by Runx in p53-deficient osteosarcoma development2022

    • Author(s)
      Kosei Ito, Tomoya Ueno, Shohei Otani, Yuki Date
    • Organizer
      第81回日本癌学会学術総会
    • Related Report
      2022 Annual Research Report
  • [Presentation] Runx3 dysregulates Myc under p53 deficiency via TGFβ-responsive Myc enhancer during osteosarcomagenesis2021

    • Author(s)
      Tomoya Ueno, Yuki Date, and Kosei Ito
    • Organizer
      第44回日本分子生物学会年会
    • Related Report
      2021 Annual Research Report
  • [Remarks] 骨肉腫発症の根本を制御する転写因子間の相互作用の解明

    • URL

      https://www.nagasaki-u.ac.jp/ja/science/science315.html

    • Related Report
      2023 Annual Research Report
  • [Remarks] 長崎大学大学院 医歯薬学総合研究科 分子硬組織生物学分野

    • URL

      https://www.de.nagasaki-u.ac.jp/dokuji/mbb/

    • Related Report
      2022 Annual Research Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi